查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1417538

ACE抑制劑市場報告：至2030年的趨勢、預測與競爭分析

ACE Inhibitors Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

ACE抑制劑的趨勢與預測

預計到2030年，全球ACE抑制劑市場將達到 60 億美元，2024年至2030年年複合成長率為 3.2%。該市場的主要促進因素包括高血壓相關疾病的增加、生物製藥開發和生產的需求增加以及改善心血管疾病的研發活動活性化。全球ACE抑制劑市場的未來充滿希望，心臟衰竭、高血壓、慢性腎臟病和糖尿病市場充滿機會。

ACE 抑制劑市場洞察

Lucintel 預測，由於對Lisinopril作為高血壓治療藥物的需求增加以及Lisinopril的使用增加以提高心臟病發作後的生存率，Lisinopril在預測期內仍將是最大的細分市場。

由於對血管張力素轉化酵素抑制劑的需求不斷增加以及目的是改進抑制劑的研發業務不斷擴大，預計北美在預測期內仍將是最大的地區。

常問問題

Q1.市場規模有多大？

A1.到2030年，全球ACE抑制劑市場預計將達到 60 億美元。

Q2.市場成長預測如何？

A2.2024年至2030年，全球ACE抑制劑市場預計將以3.2%的年複合成長率成長。

Q3.影響市場成長的主要促進因素有哪些？

A3.該市場的主要促進因素是高血壓相關疾病的增加、生物藥品市場開拓和生產需求的增加以及改善心血管疾病的研發活動的增加。

Q4.市場的主要細分市場是什麼？

A4.ACE抑制劑全球市場前景廣闊，心臟衰竭、高血壓、慢性腎臟病、糖尿病市場機會大。

Q5.市場上主要企業有哪些？

A5.生產ACE抑制劑的一些主要企業如下。

  • AstraZeneca
  • Abbott
  • Bausch Health Companies
  • Pfizer
  • AbbVie
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Eli Lilly and Company

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計，在預測期內，lisinopril將繼續成為最大的細分市場，因為對lisinopril作為治療高血壓的需求不斷成長，以及越來越多地使用lisinopril來提高心臟病發作後的存活率。

Q7.未來五年預計哪個地區將成為最大的市場？

A7.由於對血管收縮素轉化酵素抑制劑的需求增加以及目的是改進抑制劑的研究和開發的擴大，北美仍然是預測期內最大的地區。

Q8.可以客製化報告嗎？

A8.是的，Lucintel 提供 10%的客製化服務，無需額外付費。

目錄

第1章 執行摘要

第2章 全球ACE抑制劑市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球ACE抑制劑市場趨勢（2018-2023）與預測（2024-2030）
  • 依藥物類型分類的全球ACE抑制劑市場
    • Lisinopril
    • Ramipril
    • Captopril
    • Moexipril
    • Fosinopril
    • Perindopril
    • 其他
  • 全球ACE抑制劑市場（依應用）
    • 心臟衰竭
    • 高血壓
    • 慢性腎臟病
    • 糖尿病
    • 其他
  • 全球ACE抑制劑市場（依最終用途）
    • 醫院
    • 藥局
    • 網路藥局
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球ACE抑制劑市場（依地區）
  • 北美ACE抑制劑市場
  • 歐洲ACE抑制劑市場
  • 亞太ACE抑制劑市場
  • 其他地區ACE抑制劑市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球ACE抑制劑市場成長機會（依藥物類型）
    • 全球ACE抑制劑市場成長機會（依應用）
    • 全球ACE抑制劑市場成長機會（依最終用途）
    • 全球ACE抑制劑市場成長機會（依地區）
  • 全球ACE抑制劑市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球ACE抑制劑市場產能擴張
    • 全球ACE抑制劑市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • AstraZeneca
  • Abbott
  • Bausch Health Companies
  • Pfizer
  • AbbVie
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Eli Lilly and Company
簡介目錄

ACE Inhibitors Trends and Forecast

The future of the global ACE Inhibitors market looks promising with opportunities in the heart failure, hypertension, chronic kidney disease, and diabetes markets. The global ACE Inhibitors market is expected to reach an estimated $6.0 billion by 2030 with a CAGR of 3.2% from 2024 to 2030. The major drivers for this market are rising rates of hypertension-related diseases, rising demand for biopharmaceutical product development and production, as well as, growing number of research and development activities for the improvement of cardiovascular diseases.

A more than 150-page report is developed to help in your business decisions.

ACE Inhibitors by Segment

The study includes a forecast for the global ACE Inhibitors by drug type, application, end use, and region.

ACE Inhibitors Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

  • Lisinopril
  • Ramipril
  • Captopril
  • Moexipril
  • Fosinopril
  • Perindopril
  • Others

ACE Inhibitors Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Heart Failure
  • Hypertension
  • Chronic Kidney Disease
  • Diabetes
  • Others

ACE Inhibitors Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Pharmacies
  • Online Drug Stores
  • Others

ACE Inhibitors Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of ACE Inhibitors Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies ACE Inhibitors companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ACE Inhibitors companies profiled in this report include-

  • AstraZeneca
  • Abbott
  • Bausch Health Companies
  • Pfizer
  • AbbVie
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Eli Lilly and Company

ACE Inhibitors Market Insights

Lucintel forecasts that lisinopril will remain the largest segment over the forecast period due to the growing demand for lisinopril medications for the treatment of high blood pressure, as well as a growth in the use of lisinopril to improve survival after a heart attack.

North America will remain the largest region over the forecast period because of the increased demand for angiotensin-converting enzyme inhibitors, as well as the expansion of research and development operations aimed at generating improved inhibitors.

Features of the Global ACE Inhibitors Market

Market Size Estimates: Ace inhibitors market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Ace inhibitors market size by drug type, application, end use, and region in terms of value ($B).

Regional Analysis: Ace inhibitors market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug type, application, end use, and regions for the ACE Inhibitors market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ACE Inhibitors market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the ACE Inhibitors market size?

Answer: The global ACE Inhibitors market is expected to reach an estimated $6.0 billion by 2030.

Q2. What is the growth forecast for ACE Inhibitors market?

Answer: The global ACE Inhibitors market is expected to grow with a CAGR of 3.2% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the ACE Inhibitors market?

Answer: The major drivers for this market are rising rates of hypertension-related diseases, rising demand for biopharmaceutical product development and production, as well as, growing number of research and development activities for the improvement of cardiovascular diseases.

Q4. What are the major segments for ACE Inhibitors market?

Answer: The future of the global ACE Inhibitors market looks promising with opportunities in the heart failure, hypertension, chronic kidney disease, and diabetes markets.

Q5. Who are the key ACE Inhibitors market companies?

Answer: Some of the key ACE Inhibitors companies are as follows.

  • AstraZeneca
  • Abbott
  • Bausch Health Companies
  • Pfizer
  • AbbVie
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Eli Lilly and Company

Q6. Which ACE Inhibitors market segment will be the largest in future?

Answer: Lucintel forecasts that lisinopril will remain the largest segment over the forecast period due to the growing demand for lisinopril medications for the treatment of high blood pressure, as well as a growth in the use of lisinopril to improve survival after a heart attack.

Q7. In ACE Inhibitors market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period because of the increased demand for angiotensin-converting enzyme inhibitors, as well as the expansion of research and development operations aimed at generating improved inhibitors.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the ACE Inhibitors market by drug type (lisinopril, ramipril, captopril, moexipril, fosinopril, perindopril, and others), application (heart failure, hypertension, chronic kidney disease, diabetes, and others), end use (hospitals, pharmacies, online drug stores, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global ACE Inhibitors Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global ACE Inhibitors Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global ACE Inhibitors Market by Drug Type
    • 3.3.1: Lisinopril
    • 3.3.2: Ramipril
    • 3.3.3: Captopril
    • 3.3.4: Moexipril
    • 3.3.5: Fosinopril
    • 3.3.6: Perindopril
    • 3.3.7: Others
  • 3.4: Global ACE Inhibitors Market by Application
    • 3.4.1: Heart Failure
    • 3.4.2: Hypertension
    • 3.4.3: Chronic Kidney Disease
    • 3.4.4: Diabetes
    • 3.4.5: Others
  • 3.5: Global ACE Inhibitors Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Pharmacies
    • 3.5.3: Online Drug Stores
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global ACE Inhibitors Market by Region
  • 4.2: North American ACE Inhibitors Market
    • 4.2.2: North American ACE Inhibitors Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others
  • 4.3: European ACE Inhibitors Market
    • 4.3.1: European ACE Inhibitors Market by Drug Type: Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others
    • 4.3.2: European ACE Inhibitors Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others
  • 4.4: APAC ACE Inhibitors Market
    • 4.4.1: APAC ACE Inhibitors Market by Drug Type: Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others
    • 4.4.2: APAC ACE Inhibitors Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others
  • 4.5: ROW ACE Inhibitors Market
    • 4.5.1: ROW ACE Inhibitors Market by Drug Type: Lisinopril, Ramipril, Captopril, Moexipril, Fosinopril, Perindopril, and Others
    • 4.5.2: ROW ACE Inhibitors Market by Application: Heart Failure, Hypertension, Chronic Kidney Disease, Diabetes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global ACE Inhibitors Market by Drug Type
    • 6.1.2: Growth Opportunities for the Global ACE Inhibitors Market by Application
    • 6.1.3: Growth Opportunities for the Global ACE Inhibitors Market by End Use
    • 6.1.4: Growth Opportunities for the Global ACE Inhibitors Market by Region
  • 6.2: Emerging Trends in the Global ACE Inhibitors Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global ACE Inhibitors Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global ACE Inhibitors Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: AstraZeneca
  • 7.2: Abbott
  • 7.3: Bausch Health Companies
  • 7.4: Pfizer
  • 7.5: AbbVie
  • 7.6: Merck
  • 7.7: Novartis
  • 7.8: Johnson & Johnson
  • 7.9: Sanofi
  • 7.10: Eli Lilly and Company